Myelodysplasia is in the niche: novel concepts and emerging therapies

Por Bulycheva, E, Rauner, M, Medyouf, H, Theurl, I, Bornhäuser, M, Hofbauer, L C, Platzbecker, U
Publicado no Leukemia (2015)

An optimized targeted Next-Generation Sequencing approach for sensitive detection of single nucleotide variants

Por Stasik, S., Schuster, C., Ortlepp, C., Platzbecker, U., Bornhäuser, M., Schetelig, J., Ehninger, G., Folprecht, G., Thiede, C.
Publicado no Biomol Detect Quantif (2018)

Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial

Por Platzbecker, U, Sekeres, M A, Kantarjian, H, Giagounidis, A, Mufti, G J, Jia, C, Yang, A S, Fenaux, P
Publicado no Leukemia (2014)

Clonal architecture of del(5q) myelodysplastic syndromes: aberrant CD5 or CD7 expression within the myeloid progenitor compartment defines a subset with high clonal burden

Por Oelschlaegel, U, Alexander Röhnert, M, Mohr, B, Sockel, K, Herold, S, Ehninger, G, Bornhäuser, M, Thiede, C, Platzbecker, U
Publicado no Leukemia (2016)

A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes

Por Platzbecker, U, Symeonidis, A, Oliva, E N, Goede, J S, Delforge, M, Mayer, J, Slama, B, Badre, S, Gasal, E, Mehta, B, Franklin, J
Publicado no Leukemia (2017)

Azacytidine impairs NK cell activity in AML and MDS patients undergoing MRD-based pre-emptive treatment after allogeneic stem cell transplantation

Por Schönefeldt, C, Sockel, K, Wehner, R, Sopper, S, Wolf, D, Wermke, M, Thiede, C, Oelschlägel, U, Ehninger, G, Bornhäuser, M, Platzbecker, U, Schmitz, M
Publicado em 2013

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial

Por Platzbecker, U, Wermke, M, Radke, J, Oelschlaegel, U, Seltmann, F, Kiani, A, Klut, I-M, Knoth, H, Röllig, C, Schetelig, J, Mohr, B, Graehlert, X, Ehninger, G, Bornhäuser, M, Thiede, C
Publicado em 2012

Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study

Por Platzbecker, U, Braulke, F, Kündgen, A, Götze, K, Bug, G, Schönefeldt, C, Shirneshan, K, Röllig, C, Bornhäuser, M, Naumann, R, Neesen, J, Giagounidis, A, Hofmann, W-K, Ehninger, G, Germing, U, Haase, D, Wermke, M
Publicado em 2013

Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS s...

Por Cremers, E. M. P., van Biezen, A., de Wreede, L. C., Scholten, M., Vitek, A., Finke, J., Platzbecker, U., Beelen, D., Schwerdtfeger, R., Volin, L., Harhalakis, N., Blijlevens, N., Nagler, A., Kröger, N., de Witte, T.
Publicado no Ann Hematol (2016)

Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry

Por Kaifie, A., Kirschner, M., Wolf, D., Maintz, C., Hänel, M., Gattermann, N., Gökkurt, E., Platzbecker, U., Hollburg, W., Göthert, J. R., Parmentier, S., Lang, F., Hansen, R., Isfort, S., Schmitt, K., Jost, E., Serve, H., Ehninger, G., Berdel, W. E., Brümmendorf, T. H., Koschmieder, S.
Publicado no J Hematol Oncol (2016)

Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents

Por Duchmann, M, Braun, T, Micol, J-B, Platzbecker, U, Park, S, Pilorge, S, Beyne-Rauzy, O, Vey, N, Sébert, M, Gruson, B, Dumas, P-Y, Guieze, R, Chretien, M-L, Laribi, K, Chait, Y, Legros, L, Sahnes, L, Hirsch, P, Salanoubat, C, Solary, E, Fenaux, P, Itzykson, R
Publicado no Blood Cancer J (2017)

Karyotype complexity and prognosis in acute myeloid leukemia

Por Stölzel, F, Mohr, B, Kramer, M, Oelschlägel, U, Bochtler, T, Berdel, W E, Kaufmann, M, Baldus, C D, Schäfer-Eckart, K, Stuhlmann, R, Einsele, H, Krause, S W, Serve, H, Hänel, M, Herbst, R, Neubauer, A, Sohlbach, K, Mayer, J, Middeke, J M, Platzbecker, U, Schaich, M, Krämer, A, Röllig, C, Schetelig, J, Bornhäuser, M, Ehninger, G
Publicado no Blood Cancer J (2016)

Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide

Por Kayser, S, Krzykalla, J, Elliott, MA, Norsworthy, K, Gonzales, P, Hills, RK, Baer, MR, Ráčil, Z, Mayer, J, Novak, J, Žák, P, Szotkowski, T, Grimwade, D, Russell, NH, Walter, RB, Estey, EH, Westermann, J, Görner, M, Benner, A, Krämer, A, Smith, BD, Burnett, AK, Thiede, C, Röllig, C, Ho, AD, Ehninger, G, Schlenk, RF, Tallman, MS, Levis, MJ, Platzbecker, U
Publicado no Leukemia (2017)